Molecular biology of AMP deaminase deficiency

Area of Science:

• Biochemistry and Molecular Biology
• Human Genetics
• Enzymology

Background:

• At least four adenosine monophosphate deaminase (AMPD) isoforms exist in humans: myoadenylate deaminase (skeletal muscle), L isoform (liver), and E1/E2 isoforms (erythrocytes).
• These isoforms are encoded by distinct genes: AMPD1 (skeletal muscle), AMPD2 (liver), and AMPD3 (erythrocytes).
• Myoadenylate deaminase deficiency affects 2-3% of muscle biopsies, with an inborn form caused by specific mutations in the AMPD1 gene.

Purpose of the Study:

• To investigate the genetic basis and prevalence of adenosine monophosphate deaminase (AMPD) deficiencies in humans.
• To understand the molecular mechanisms underlying myoadenylate deaminase deficiency and its associated mutations.
• To explore the clinical implications and molecular basis of liver and erythrocyte AMPD disorders.

Main Methods:

• Analysis of AMPD gene sequences and mutations (e.g., C34-->T, C143-->T in AMPD1).
• Population genetic studies to determine the frequency of mutant alleles.
• Examination of alternatively spliced mRNA transcripts in relation to enzyme function.

Main Results:

• The inborn myoadenylate deaminase deficiency is associated with a single mutant allele containing two specific mutations (C34-->T and C143-->T).
• The mutant AMPD1 allele frequency is 0.12 in Caucasian Americans and Germans.
• Alternative splicing of AMPD1 transcripts can result in catalytically active enzymes, even with the C34-->T mutation.

Conclusions:

• Myoadenylate deaminase deficiency is a relatively common genetic condition in skeletal muscle, linked to specific AMPD1 mutations and allele frequencies.
• While the molecular basis of liver AMPD deficiency (linked to gout) and erythrocyte AMPD deficiency (asymptomatic) is not yet elucidated, these conditions represent distinct clinical entities.
• Further research is needed to fully understand the molecular underpinnings of liver and erythrocyte AMPD disorders.